ASKA Pharmaceutical Holdings (4886) · InitiativeFirst stated
Joint Research on Novel Antibody Drugs With Perseus Proteomics Inc.
First written in FY2026. . Latest entry: FY2026.
2entries
1years
1from disclosures
How it moved
Same theme, other companies
Joint Research on Novel Antibody Drugs With Perseus Proteomics Inc.A theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2026First statedAnnual report
「2025年11月に株式会社ペルセウスプロテオミクスと新規抗体医薬創出を目指し共同研究契約を締結しております。」
新規抗体医薬の創出を目的とする株式会社ペルセウスプロテオミクスとの共同研究契約を2025年11月に締結した。 - 2026-05-11First statedEarnings
「In November 2025, we entered into a joint research agreement with Perseus Proteomics Inc. to create novel antibody drugs.」
The company newly reported a joint research agreement with Perseus Proteomics Inc. aimed at creating novel antibody drugs.